Immunological issues in anti-meningococcal vaccination
Abstract number: S393
Meningococcal infections continue to cause significant morbidity and mortality, especially in young children and adolescents in Europe where Neisseria meningitidis serogroups B and C cause the majority of disease. While no effective licensed vaccine exists for Group B, vaccines consisting of the purified capsule of serogroup C (and A, W and Y) have existed for many years. Their use has been limited to outbreak control and for travellers due to (i) the limited duration of protection afforded after a single dose and (ii) their poor immunogenicity in young infants. Conjugate meningococcal C vaccines, which overcome these limitations, were the first meningococcal conjugate vaccines to be licensed and entered use first in the United Kingdom in 1999 and subsequently introduced in many European countries where they have had an impressive impact on reducing the incidence of infection. Ongoing surveillance of meningococcal infection following introduction of the vaccine together with immunological studies has provided insights into the mechanism of immune protection and the role of immunological memory. These will be discussed and the areas that remain poorly understood highlighted.
|Session name:||18th European Congress of Clinical Microbiology and Infectious Diseases|
|Back to top|